The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Sylvester, Dana-Farber researchers receive $7M from PCORI to study diet, exercise effects on mental and physical functioning in older cancer survivors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and Dana Farber Cancer Institute have received $7 million from the Patient-Centered Outcomes Research Institute to study how diet and exercise impact mental and physical functioning in older cancer survivors and their caregivers.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Mina Sedrak and Vijaya Raj Bhatt to co-lead Alliance’s committee on cancer care for older adults

Mina Sedrak, director of the UCLA Center for Cancer and Aging and director of Cancer Control and Survivorship Research at the UCLA Health Jonsson Comprehensive Cancer Center, and Vijaya Raj Bhatt professor and medical director of the Leukemia Program at the University of Nebraska Medical Center, were selected to serve as co-chairs of the Cancer in the Older Adult Committee for The Alliance for Clinical Trials in Oncology.
Clinical Roundup

ACS warns of increase in U.S. food deserts

A study by researchers at the American Cancer Society showed that between 2003 and 2023, nearly five million people in the United States lived in food deserts—places with no grocery stores. Most of these deserts are in poor and rural areas and in places where people rely on public transit. At the same time, the number of food swamps or areas with mostly restaurants/fast-food locations increased nationwide. 
Clinical

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out. 
By Jacquelyn Cobb
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account